MorphoSys AG Stock price

Equities

MOR

DE0006632003

Biotechnology & Medical Research

Real-time Estimate Tradegate 09:14:37 2024-03-28 am EDT 5-day change 1st Jan Change
67.21 EUR +0.01% Intraday chart for MorphoSys AG +1.33% +97.65%
Sales 2024 * 252M 271M Sales 2025 * 325M 350M Capitalization 2.53B 2.72B
Net income 2024 * -182M -196M Net income 2025 * -115M -124M EV / Sales 2024 * 10.3 x
Net Debt 2024 * 59.37M 64.01M Net cash position 2025 * 241M 259M EV / Sales 2025 * 7.04 x
P/E ratio 2024 *
-17.4 x
P/E ratio 2025 *
-32.6 x
Employees 524
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.15%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.01%
1 week+1.33%
Current month+3.38%
1 month+3.19%
3 months+93.72%
6 months+154.84%
Current year+97.65%
More quotes
1 week
67.06
Extreme 67.06
67.28
1 month
64.88
Extreme 64.88
67.28
Current year
29.73
Extreme 29.73
67.28
1 year
13.90
Extreme 13.9
67.28
3 years
11.81
Extreme 11.805
80.14
5 years
11.81
Extreme 11.805
146.30
10 years
11.81
Extreme 11.805
146.30
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 19-08-31
Director of Finance/CFO 45 23-08-06
Chief Tech/Sci/R&D Officer - 21-07-31
Members of the board TitleAgeSince
Director/Board Member 69 18-05-16
Director/Board Member 67 18-05-16
Chairman 69 12-05-30
More insiders
Date Price Change Volume
24-03-28 67.22 +0.03% 42 693
24-03-27 67.2 -0.03% 84,006
24-03-26 67.22 +0.09% 138,582
24-03-25 67.16 -0.03% 169,514
24-03-22 67.18 +1.30% 399,822

Delayed Quote Xetra, March 28, 2024 at 05:40 am EDT

More quotes
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
67.2 EUR
Average target price
58.71 EUR
Spread / Average Target
-12.63%
Consensus
  1. Stock
  2. Equities
  3. Stock MorphoSys AG - Xetra